Illumina, Inc. (NASDAQ:ILMN) SVP Oene Mark Van sold 1,091 shares of the business’s stock in a transaction that occurred on Tuesday, September 4th. The shares were sold at an average price of $354.18, for a total value of $386,410.38. Following the completion of the transaction, the senior vice president now directly owns 11,126 shares in the company, valued at approximately $3,940,606.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

ILMN traded down $3.03 during trading on Friday, reaching $345.26. 22,709 shares of the stock were exchanged, compared to its average volume of 895,554. The company has a debt-to-equity ratio of 0.22, a quick ratio of 2.44 and a current ratio of 2.74. The company has a market cap of $50.91 billion, a price-to-earnings ratio of 86.78, a PEG ratio of 2.87 and a beta of 0.97. Illumina, Inc. has a 1 year low of $196.00 and a 1 year high of $357.93.

Illumina (NASDAQ:ILMN) last posted its earnings results on Monday, July 30th. The life sciences company reported $1.43 EPS for the quarter, topping the Zacks’ consensus estimate of $1.11 by $0.32. The company had revenue of $830.00 million for the quarter, compared to the consensus estimate of $786.88 million. Illumina had a return on equity of 26.64% and a net margin of 20.88%. Illumina’s quarterly revenue was up 25.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.82 earnings per share. analysts predict that Illumina, Inc. will post 5.46 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of ILMN. Jennison Associates LLC lifted its position in shares of Illumina by 4.5% in the second quarter. Jennison Associates LLC now owns 4,297,581 shares of the life sciences company’s stock valued at $1,200,271,000 after acquiring an additional 185,745 shares in the last quarter. Fred Alger Management Inc. lifted its position in shares of Illumina by 21.4% in the second quarter. Fred Alger Management Inc. now owns 778,450 shares of the life sciences company’s stock valued at $217,413,000 after acquiring an additional 137,302 shares in the last quarter. American Century Companies Inc. lifted its position in shares of Illumina by 19.2% in the first quarter. American Century Companies Inc. now owns 761,796 shares of the life sciences company’s stock valued at $180,104,000 after acquiring an additional 122,612 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in shares of Illumina by 5.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 604,615 shares of the life sciences company’s stock valued at $168,863,000 after acquiring an additional 31,985 shares in the last quarter. Finally, Millennium Management LLC lifted its position in shares of Illumina by 219.8% in the second quarter. Millennium Management LLC now owns 548,957 shares of the life sciences company’s stock valued at $153,318,000 after acquiring an additional 377,283 shares in the last quarter. Institutional investors own 89.78% of the company’s stock.

A number of research analysts have recently issued reports on the company. Cowen boosted their target price on Illumina from $275.00 to $315.00 and gave the company an “outperform” rating in a report on Tuesday, July 10th. BidaskClub raised Illumina from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 1st. Citigroup upped their price objective on Illumina from $275.00 to $330.00 and gave the stock a “buy” rating in a report on Monday, June 25th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $350.00 price objective on shares of Illumina in a report on Tuesday, July 31st. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $340.00 price objective (up previously from $330.00) on shares of Illumina in a report on Friday, July 27th. Five investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $308.25.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Further Reading: How to Use a Moving Average for TradingĀ 

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.